Astria Therapeutics, Inc. Share Price

Equities

ATXS

US04635X1028

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 17/07/2024 BST 5-day change 1st Jan Change
11.33 USD -4.31% Intraday chart for Astria Therapeutics, Inc. +8.73% +47.53%
Sales 2024 * - Sales 2025 * - Capitalization 622M 47.85B
Net income 2024 * -89M -6.84B Net income 2025 * -112M -8.61B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-6.69 x
P/E ratio 2025 *
-6.66 x
Employees 59
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.7%
More Fundamentals * Assessed data
Dynamic Chart
Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $29, Maintains Outperform Rating MT
Astria Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating MT
Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee CI
Wedbush Raises Astria Therapeutics' PT to $22 From $17 After Reporting Top-Line Phase 1/2 ALPHA-STAR Results for STAR-0215 Program; Maintains Outperform Rating MT
Transcript : Astria Therapeutics, Inc. - Special Call
Astria Therapeutics, Inc. Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE CI
North American Morning Briefing : Markets on Hold -2- DJ
Astria Therapeutics, Inc.(NasdaqGM:ATXS) added to S&P Biotechnology Select Industry Index CI
Certain Stock Options of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024. CI
Certain Common Stock of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024. CI
Astria Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Astria Therapeutics Shares Rise After Pricing of $125 Million Underwritten Offering MT
Astria Therapeutics Files $500 Million Mixed Shelf MT
Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $30, Maintains Outperform Rating MT
More news

Latest transcript on Astria Therapeutics, Inc.

1 day-4.31%
1 week+8.73%
Current month+24.51%
1 month+28.31%
3 months+7.39%
6 months+49.87%
Current year+47.53%
More quotes
1 week
11.27
Extreme 11.2703
12.25
1 month
8.67
Extreme 8.67
12.25
Current year
6.58
Extreme 6.58
16.90
1 year
4.26
Extreme 4.26
16.90
3 years
2.36
Extreme 2.36
16.90
5 years
2.36
Extreme 2.36
51.54
10 years
2.36
Extreme 2.36
1 017.60
More quotes
Managers TitleAgeSince
Founder 56 25/06/08
Director of Finance/CFO 51 31/03/11
Chief Tech/Sci/R&D Officer 54 14/07/22
Members of the board TitleAgeSince
Chairman 73 31/12/13
Director/Board Member 65 03/01/19
Director/Board Member 75 04/04/16
More insiders
Date Price Change Volume
17/07/24 11.33 -4.31% 357,946
16/07/24 11.84 +0.08% 293,436
15/07/24 11.83 +3.23% 357,327
12/07/24 11.46 +1.87% 328,320
11/07/24 11.25 +7.97% 429,784

Delayed Quote Nasdaq, July 17, 2024 at 09:00 pm

More quotes
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
11.33 USD
Average target price
24.71 USD
Spread / Average Target
+118.13%
Consensus